Evidence map›Paper›PMID 40337510›Full record

ArticleFrontiers in pharmacology2025

Clusterin ameliorates diabetic atherosclerosis by suppressing macrophage pyroptosis and activation.

Lingling Xuan, Lulu Ren, Xiaoxu Kang, Rui Chang, Wen Zhang, Lili Gong, Lihong Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lingling Xuan *Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Lulu Ren *Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Xiaoxu KangInstitute of Clinical Medical Sciences, China-Japan Friendship Hospital, Capital Medical University, Beijing, China.
Rui ChangInstitute of Clinical Medical Sciences, China-Japan Friendship Hospital, Capital Medical University, Beijing, China.
Wen ZhangDepartment of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Lili GongInstitute of Clinical Medical Sciences, China-Japan Friendship Hospital, Capital Medical University, Beijing, China.
Lihong LiuInstitute of Clinical Medical Sciences, China-Japan Friendship Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: It has been demonstrated that clusterin (CLU) is a protective protein involved in a variety of diseases and disorders. However, the role of CLU in diabetic atherosclerosis is not elucidative. The objective of this study is to investigate the role of CLU in diabetic atherosclerosis and the molecular mechanisms. Method: In Results: We found that Conclusion: Our study revealed that CLU could ameliorate diabetic atherosclerosis via suppressing inflammatory factors release and pyroptosis of macrophage. CLU may be a promising therapeutic target for diabetic atherosclerosis.

Indexed as

atherosclerosisclusterindiabetesinflammationmacrophage pyroptosis

Identifiers

PMID40337510
PMCPMC12055819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.